Risks for childhood Hodgkin lymphoma

Last medical review:

Some things can affect your child's risk, or chance, of developing cancer. Certain behaviours, substances or conditions can increase or decrease the risk. Most cancers are the result of many risks. But sometimes cancer develops in children who don't have any risks.

Hodgkin lymphoma (HL) can develop in children of any age but occurs most frequently in teenagers and young adults 15 to 30 years old. More boys than girls develop childhood HL.

Some studies also suggest children with Asian, Pacific Islander or Indigenous heritage may be less likely to develop HL than children of other ethnicities. More research is needed to confirm and determine why.

A few things could increase your child's risk of HL. Most of these risks can't be changed. Until we learn more about these risks, there are no specific ways to lower your child's risk for HL.

The following can increase the risk for childhood HL:

Certain infections

Family history of Hodgkin lymphoma

Weak immune system

Genetic conditions

Certain infections

Infections with the following viruses increase the risk of developing childhood HL.

Epstein-Barr virus (EBV) is a type of herpes virus that causes infectious mononucleosis (also called mono, or the kissing disease).

Learn more about Epstein-Barr virus (EBV).

The human immunodeficiency virus (HIV) is the virus that causes AIDS. HIV weakens the body's immune system and may leave people vulnerable to infection and certain types of cancer. Infection with HIV increases the risk of HL in children.

Learn more about human immunodeficiency virus (HIV).

Family history of HL

Children with a sibling who has or had Hodgkin lymphoma have an increased risk of HL. The risk is greater if this sibling is their twin, and greatest if they are identical twins. A child's risk of developing HL is also increased when a parent has or had the disease, but not as much as when their sibling has developed it.

More research is needed to determine why a family history of HL increases a child's risk of developing the disease.

Weak immune system

Having a weak immune system (called immunosuppression) increases a child's risk for HL. Your child may have a weak immune system for different reasons. A child's immune system can be weakened by:

  • HIV (the virus that causes AIDS)
  • medicines to suppress their immune system after they had an organ transplant
  • genetic conditions that cause immunodeficiency (a weakened immune system)

Genetic conditions

A genetic condition is a disease caused by a change (mutation) in one or more genes. Having certain genetic conditions increases a child's risk of developing HL.

Ataxia-telangiectasia is an inherited disease that affects the nervous system, immune system and other body systems. Signs and symptoms include loss of balance, poor coordination, frequent infections, red eyes (due to widening of blood vessels) and abnormal eye movements. Ataxia-telangiectasia is associated with an increased risk of developing some cancers, including HL, leukemia and lymphoma.

Nijmegen breakage syndrome is an inherited condition that causes a weak immune system, slow growth in early childhood, a smaller than average head size (called microcephaly) and premature ovarian failure. Nijmegen breakage syndrome increases the risk of developing HL and non-Hodgkin lymphoma (NHL).

Wiskott-Aldrich syndrome is an inherited condition that affects the blood cells and the cells of the immune system. It usually only affects boys. Wiskott-Aldrich syndrome increases the risk of developing HL, NHL and acute myeloid leukemia (AML).

Possible risks

The following have been linked with an increased risk of childhood HL, but more research is needed to know for sure that they are risks:

  • less exposure to infections in early childhood
  • socio-economic status
  • high weight at birth

Expert review and references

  • Canadian Cancer Society | Société canadienne du cancer
  • Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. Journal of Global Health. 2020: 10(1): 010405.
  • Carbone A, Gloghini A, Serraino D, Spina M, Tirelli U, Vaccher E. Immunodeficiency-associated Hodgkin lymphoma. Expert Review of Hematology. 2021: 14(6): 547–559.
  • Chun GYC, Sample J, Hubbard AK, Spector LG, Williams LA. Trends in pediatric lymphoma incidence by global region, age and sex from 1988-2012. Cancer Epidemiology. 73: 101965.
  • Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J . Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adult. American Journal of Epidemiology. 2012: 176(12): 1147–1158.
  • Engels EA, Hildesheim A. Immunologic factors. Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: Kindle version, [chapter 25] https://read.amazon.ca/?asin=B0777JYQQC&language=en-CA.
  • Hjalgrim H, Chang ET, Glasser SL. Hodgkin lymphoma. Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: Kindle version, [chapter 39] https://read.amazon.ca/?asin=B0777JYQQC&language=en-CA.
  • International Agency for Research on Cancer (IARC). Volume 100B: Biological agents: A Review of Human Carcinogens. 2012: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B.pdf.
  • Jones SJ, Stroshein S, Williams AM, et al. Birth order, sibship size, childhood environment and immune-related disorders, and risk of lymphoma in lymphoid cancer families. Cancer Epidemiology, Biomarkers and Prevention. 2020: 29(6): 1168–1178.
  • Linabery AM, Erhardt EB, Richardson MR, et al. Family risk of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. International Journal of Cancer. 2015: 137(9):2163–2174.
  • Marcotte EL, Domingues AM, Sample JM, Richardson MR, Spector LG. Racial and ethnic disparities in pediatric cancer incidence among children and young adults in the United States by single year of age. Cancer. 2021: 127(19): 3651–3663.
  • Munir F, Hardit V, Sheikh IN, et al . Classical Hodgkin lymphoma: From past to future–A comprehensive review of pathophysiology and therapeutic advances. International Journal of Molecular Sciences. 2023: 24(12): 10095.
  • National Toxicology Program. Report on Carcinogens. 15 ed. Research Triangle Park, NC: US Department of Health and Human Services, Public Health Service; 2021: https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html.
  • Pereira V, Boudiemaa S, Besson C, et al. Epstein-Barr Virus in childhood and adolescent classic Hodgkin lymphoma in a French cohort of 301 patients. Journal of Pediatric Hematology/Oncology. 2022: 44(8): e1033–e1038.
  • Rashti R, Ghasemi F, Poorolajal J. Association between birth weight and risk of nonneurological childhood cancers: a systematic review and meta-analysis. European Journal of Cancer Prevention. 2024.
  • Roman E, Lightfoot T, Picton S, Kinsey S. Childhood cancers. Thun MJ, Linet MS, Cerhan JR, Haiman CA Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: 59.
  • Stacy SL, Buchanich JM, Ma ZQ, et al. Maternal obesity, birth size, and risk of childhood cancer development. American Journal of Epidemiology. 2019: 188(8): 1503–1511.
  • Yuan T, Hu Y, Zhou X, et al. Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis. eClinicalMedicine. 2022: 52: 101613.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society